NCT06130540 - Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

March 12, 2025

Study Completion Date

April 2, 2025

Conditions

Giant Cell ArteritisPolymyalgia Rheumatica

Interventions

DRUG

Secukinumab

Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8

Trial Locations (19)

3010

Novartis Investigative Site, Bern

4031

Novartis Investigative Site, Basel

9007

Novartis Investigative Site, Sankt Gallen

15706

Novartis Investigative Site, Santiago de Compostela

16635

Altoona Center for Clin Res, Duncansville

25801

Rheumatology Pulmonary Clinic, Beckley

28009

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

33486

Rheumatology Associates of South Florida, Boca Raton

33542

FL Medical Clinic Orlando Health, Zephyrhills

38305

West Tennessee Research Institute, Jackson

42123

Novartis Investigative Site, Reggio Emilia

50134

Novartis Investigative Site, Florence

60527

Willow Rheumatology Wellness, Willowbrook

78229

Accurate Clinical Research Inc, San Antonio

98004

Overlake Internal Med Associates, Bellevue

625 00

Novartis Investigative Site, Brno Bohunice

686 01

Novartis Investigative Site, Uherské Hradiště

1649 035

Novartis Investigative Site, Lisbon